ES2159734T3 - Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. - Google Patents

Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.

Info

Publication number
ES2159734T3
ES2159734T3 ES96914621T ES96914621T ES2159734T3 ES 2159734 T3 ES2159734 T3 ES 2159734T3 ES 96914621 T ES96914621 T ES 96914621T ES 96914621 T ES96914621 T ES 96914621T ES 2159734 T3 ES2159734 T3 ES 2159734T3
Authority
ES
Spain
Prior art keywords
represented
derivatives
heteroarilalquenilic
cyclopentan
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914621T
Other languages
English (en)
Inventor
Robert M Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2159734T3 publication Critical patent/ES2159734T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE DERIVADOS DE PROSTAGLANDINAS DE TIPO F COMO HIPOTENSORES OCULARES. LOS DERIVADOS DE PGF UTILIZADOS DE ACUERDO CON LA INVENCION ESTAN REPRESENTADOS POR LA FORMULA (I), EN QUE LAS UNIONES REPRESENTADAS POR LINEAS ONDULADAS INDICAN CONFIGURACION TANTO ALFA AL} COMO BETA BE}; LOS SEGMENTOS SOMBREADOS INDICAN CONFIGURACION AL}; LOS TRIANGULOS SOLIDOS SE UTILIZAN PARA INDICAR CONFIGURACION BE}, LOS ENLACES REPRESENTADOS CON LINEA DE PUNTOS REPRESENTAN UN DOBLE ENLACE O UN ENLACE SIMPLE, R ES UN RADICAL HETEROARILO SUSTITUIDO, R SUP,1} ES HIDROGENO O UN RADICAL ALQUILO INFERIOR QUE POSEE HASTA SEIS ATOMOS DE CARBONO, X SE SELECCIONA DEL GRUPO FORMADO POR REPRESENTA DOS RADICALES HIDROGENO. CIERTOS COMPUESTOS REPRESENTADOS POR LA FORMULA (I) CONSTITUYEN OTRO ASPECTO DE LA PRESENTE INVENCION.
ES96914621T 1995-05-18 1996-05-14 Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. Expired - Lifetime ES2159734T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44399295A 1995-05-18 1995-05-18

Publications (1)

Publication Number Publication Date
ES2159734T3 true ES2159734T3 (es) 2001-10-16

Family

ID=23763030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914621T Expired - Lifetime ES2159734T3 (es) 1995-05-18 1996-05-14 Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.

Country Status (7)

Country Link
EP (1) EP0825980B1 (es)
JP (1) JPH11505802A (es)
AU (1) AU693698B2 (es)
CA (1) CA2221110C (es)
DE (1) DE69613693T2 (es)
ES (1) ES2159734T3 (es)
WO (1) WO1996036599A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
EP0968183A2 (en) 1997-03-07 2000-01-05 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
JP4834224B2 (ja) * 1999-03-05 2011-12-14 デューク ユニバーシティ C16不飽和fp−選択的プロスタグランジン類縁体
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
US6395787B1 (en) * 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
MXPA04004164A (es) 2001-11-05 2004-09-06 Allergan Inc Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2.
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド EP2受容体作動剤としてのω−シクロアルキル17−ヘテロアリールプロスタグランジンE2類似体
US7429669B2 (en) * 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016520561A (ja) 2013-04-12 2016-07-14 アラーガン、インコーポレイテッドAllergan,Incorporated 脂肪減少のためのビマトプロスト、ビマトプロスト類似体、プロスタミド及びプロスタグランジンの持続放出
SG11201604787SA (en) * 2013-12-13 2016-07-28 Allergan Inc Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
WO2016176640A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
WO2019023211A1 (en) 2017-07-25 2019-01-31 Allergan, Inc. SOLID COMPLEX COMPRISING (Z) -7 - ((1R, 2R, 3R, 5S) -2 - ((S, E) -5- (2,5-DICHLOROTHIOPHEN-3-YL) -3-HYDROXYPENT-1 EN-1-YL) -3,5-DIHYDROXYCYCLOPENTYL) HEPT-5-ENAMIDE, PREPARATION THEREOF AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1300150T1 (de) * 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy

Also Published As

Publication number Publication date
AU693698B2 (en) 1998-07-02
DE69613693T2 (de) 2002-05-16
EP0825980A1 (en) 1998-03-04
CA2221110C (en) 2009-08-04
AU5792496A (en) 1996-11-29
CA2221110A1 (en) 1996-11-21
WO1996036599A1 (en) 1996-11-21
JPH11505802A (ja) 1999-05-25
EP0825980B1 (en) 2001-07-04
DE69613693D1 (de) 2001-08-09

Similar Documents

Publication Publication Date Title
ES2159734T3 (es) Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ES2157424T3 (es) Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
ES2031841T3 (es) Un procedimiento para la preparacion de derivados de 1,1-dioxido de 2-aminoalquil-1,2-benzoisotiazol-3-(2h)ona.
PA8463501A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ES2161290T3 (es) Derivados de quinazolina.
ES2076147T3 (es) Nuevos derivados de amina ciclicos, medicamento que contiene estos compuestos y procedimiento para su preparacion.
MX7012A (es) Procedimiento para preparar derivados de acido-cis,endo-2-azabiciclo-(5.3.0.)-decan-3-carboxilico.
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
PT92821A (pt) Processo para a preparacao composicoes farmaceuticas para o combate de doencas do tipo psoriase, bem como doencas inflamatorias, incorporando azelastina como substancia activa
ES2072263T3 (es) Derivados de 4-aminopiridina.
SE8703854D0 (sv) Prostaglandinderivat for behandling av glaukom eller okuler hypertension
ES2038074A1 (es) Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2170956T3 (es) Derivados 2-alquenilicos de acido ciclopentan(en)oico como agentes terapeuticos en el tratamiento de hipertension ocular.
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
ES2179857T3 (es) Derivados de quinoleina sustituidos, procedimiento para su preparacion y su utilizacion.
ES2128554T3 (es) Nuevos derivados del acido glutamico, procedimiento para su preparacion y su utilizacion como medicamentos para el aumento de la memoria y aprendizaje.
ES2196001T3 (es) Derivado de pirroloazepina.
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
ES2066905T3 (es) Heterociclos substituidos con amino como inhibidores de renina.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 825980

Country of ref document: ES